These results indicate that SREBP2, a potentially actionable target, could be used along with low aPKC and high ANXA10/MUC5A as biomarkers for the identification and selective treatment of serrated CRC subtypes that, although they might be refractory to conventional therapy, would be addicted to the cholesterol pathway, creating a potential clinical vulnerability. This evidence concerns the gene ANXA10 and colorectal carcinoma.